FSSAI Pulls Up Nestle and HUL for Misleading Claims
The Food Safety and Standards Authority of India has issued show-cause notices against food FMCG giants Nestle India and Hindustan Unilever. Specifically, the regulator highlighted widespread FSSAI misleading claims across popular commercial health drinks and nutritional supplements. These enforcement actions target unsubstantiated therapeutic assertions that mislead vulnerable consumer groups. Therefore, medical practitioners across India must evaluate commercially marketed supplements with heightened vigilance.
Regulatory Scrutiny and FSSAI Misleading Claims
Food safety regulators discovered multiple non-compliances spanning product packaging and digital commerce portals. For instance, Nestle India received notices regarding its ready-to-drink Nescafe portfolio. The manufacturer labeled containers as flavoured milk on the front but declared proprietary dairy drinks on the reverse. In addition, digital listings marketed the products using unapproved promotional statements. Consequently, FSSAI cited clear violations of packaging and advertising standards. The regulator emphasized that food business operators cannot bypass standard classification categories.
Violations Flagged in Maternal and Bone Formulations
Hindustan Unilever faced rigorous scrutiny over its widely consumed Horlicks formulations. In particular, the regulator flagged Horlicks Mother's Plus for claiming to ensure a healthy birth weight. Such absolute assertions violate statutory claim regulations by implying guaranteed clinical outcomes for neonates. Furthermore, Horlicks Women's Plus promoted unapproved bone and muscle health benefits. The company claimed no added sugar despite adding maltodextrin, which rapidly elevates blood glucose levels. Additionally, the product failed to substantiate its hundred percent recommended dietary allowance claims. Hence, healthcare providers must guide patients regarding hidden carbohydrates in commercial drinks.
Clinical Implications for Chronic Kidney Disease Supplements
Specialised clinical nutrition products also faced serious regulatory sanctions during the inspection drive. For example, FSSAI scrutinized Nestle Resource Renal vanilla flavour powder. The manufacturer marketed the formulation for conservatively treated chronic kidney disease patients without obtaining mandatory prior approval. Moreover, the packaging failed to display mandatory vegetarian or non-vegetarian origin logos. Renal patients require strict mineral, electrolyte, and protein control to prevent metabolic crises. Therefore, unverified nutritional powders can pose grave risks to individuals with impaired renal clearance. Clinicians must ensure that patients consume only verified foods for special medical purposes.
Frequently Asked Questions
Q1: Why did FSSAI issue notices to Nestle and HUL?
FSSAI issued notices because the companies displayed misleading nutritional claims, omitted mandatory approvals, and created label inconsistencies.
Q2: Why is the no added sugar label controversial when maltodextrin is present?
Maltodextrin is a high-glycemic carbohydrate that spikes serum glucose. Consequently, marketing such products as containing no added sugar misleads diabetic and metabolic patients.
Q3: What regulatory requirements apply to special medical purpose foods in India?
Under the 2022 FSSAI regulations, foods for special medical purposes require formal prior approval before commercial retail sale.
References
- FSSAI issues notices to Nestle India, Hindustan Unilever for misleading claims - ETHealthworld
- Food Safety and Standards (Advertising and Claims) Regulations, 2018 - Food Safety and Standards Authority of India (FSSAI)
- Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, and Prebiotic and Probiotic Food) Regulations, 2022 - FSSAI
